Metavir Fibrosis Stage F0–F1
Metavir fibrosis stage F0 indicates no fibrosis. [1] Metavir fibrosis stage F1 indicates portal fibrosis without septa (mild, minimal scarring). [2] Overall, F0–F1 corresponds to minimal fibrosis and lower risk of near-term hepatic decompensation compared with advanced fibrosis stages. [1]
Clinical Interpretation of F0–F1
F0–F1 generally indicates absence of architectural distortion typical of septal formation or cirrhosis. [1] Stage F1 reflects mild portal-based fibrotic change without septa. [2] Fibrosis staging should be integrated with the underlying cause of liver disease because prognosis and management depend on etiology and activity, not fibrosis stage alone. [1]
Etiology-Directed Management
Management should target the cause of liver injury and the risk of progression. [1] For chronic hepatitis C, treatment decisions are guided by current standards for HCV care rather than by biopsy-only fibrosis severity, with post–sustained virologic response care based on whether fibrosis is advanced or not. [3] For nonalcoholic fatty liver disease (NAFLD), risk stratification should use noninvasive testing that estimates fibrosis risk and should guide monitoring intensity and need for further evaluation. [4] For chronic hepatitis B, treatment indication is driven by virologic activity and liver disease severity and is not determined by Metavir stage alone; fibrosis stage can contribute to severity assessment. [5]
Evaluation to Guide Ongoing Care
Noninvasive fibrosis assessment should be used to confirm low-risk status and to stratify monitoring intensity. [4] For NAFLD evaluation, FIB-4 is recommended as an initial risk tool, with escalation to secondary assessment when FIB-4 is elevated. [4] Secondary risk stratification for elevated FIB-4 should preferentially use vibration-controlled elastography (VCTE) or Enhanced Liver Fibrosis (ELF). [4] Liver biopsy should be considered when noninvasive testing suggests significant fibrosis (≥F2) or when additional/alternate diagnoses are suspected. [4]
Treatment Initiation Thresholds by Common Etiologies
For NAFLD, management does not escalate to advanced-fibrosis pathways when fibrosis risk is low, while higher-risk features should trigger secondary assessment and specialist evaluation. [4] For chronic hepatitis B, treatment is typically indicated based on HBV DNA level plus ALT and evidence of at least moderate necroinflammatory activity and/or fibrosis, rather than on F0–F1 alone. [5] For chronic hepatitis C, advanced fibrosis (Metavir F3–F4) is a highest-priority treatment group, while patients without advanced fibrosis (Metavir F0–F2) who achieve SVR should receive standard medical care recommended for patients who were never infected, with ongoing attention to other liver risk factors. [3]
Targets and Goals of Therapy
The primary goals are prevention of fibrosis progression and prevention of liver-related complications. [1] In treated hepatitis C with SVR and without advanced fibrosis, the goal is maintenance of standard preventive care because progression of liver injury is largely halted, while coexisting liver disease risks can persist. [3] In NAFLD, goals include identifying patients at risk for progression and aligning monitoring frequency and intensity with fibrosis risk estimates. [4]
Common Pitfalls to Avoid
Fibrosis stage should not be managed in isolation because coexisting liver diseases can drive ongoing risk even when Metavir fibrosis is F0–F1. [3] In chronic hepatitis C, failure to address other progression drivers after SVR is a key risk (for example, metabolic liver disease, alcohol use, iron overload, or hepatitis B). [3] In NAFLD, relying on a single fibrosis estimate without risk-based reassessment can miss progression risk in higher-risk metabolic phenotypes. [4]
Surveillance and Follow-Up
For NAFLD, follow-up intensity should be based on fibrosis risk stratification using FIB-4 and secondary testing when FIB-4 is elevated. [4] For NAFLD patients with prediabetes or type 2 diabetes or multiple metabolic risk factors, more frequent FIB-4 monitoring (every 1–2 years) should be considered. [4] For hepatitis C patients without advanced fibrosis who achieve SVR, follow-up should focus on standard medical care while monitoring for other liver disease risks. [3]